Structure Therapeutics (GPCR) “announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares, each representing three ordinary shares, or for certain investors that so choose, in lieu of ADSs, pre-funded warrants to purchase ordinary shares, represented by ADSs. All securities are being offered by Structure Therapeutics. Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering. LifeSci Capital and Citizens Capital Markets are acting as co-managers for the proposed offering.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $90 from $50 at Stifel
- Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation
- Structure Therapeutics ACCESS data validates ‘bull case,’ says H.C. Wainwright
- Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment
- Structure Therapeutics rises 101.6%